Pfiz­er, still chas­ing Dupix­ent, re­leas­es fifth round of da­ta for eczema JAK in­hibitor abroc­i­tinib

Over the last sev­er­al months, Pfiz­er has been putting to­geth­er a pro­file of sev­er­al Phase III tri­als for its ex­per­i­men­tal JAK1 in­hibitor abroc­i­tinib to take …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER